AGM Statement

8 Jun 2006 07:03

Amphion Innovations PLC08 June 2006 Amphion Innovations plc Annual General Meeting Trading Update London, UK, 8 June 2006 - The Annual General Meeting of Amphion Innovations plc(LSE: AMP), the developer of companies in the life sciences and medicaltechnology sectors, will be held in London today. We are providing thefollowing trading update summarising promising progress made regarding some ofour Partner Companies following on from the preliminary results announcement of8 March 2006: Durham Scientific Crystals, Ltd. We are delighted to announce that Durham Scientific Crystals (DSC) this pastmonth won the prestigious North East Business Association's Regional InnovationCompany of the Year Award for 2006, sponsored by Barclay's Bank. DSC hadpreviously won the North East Business Association's regional "TechnologyCompany of the Year" award in 2005, sponsored by O2. Based in England's NorthEast region, DSC is advancing world-leading technology developed at DurhamUniversity, dedicated to the field of medical imaging. DSC also recently won a development contract worth £680,000 (approximately US$1.3 million) from Cenamps (the Centre of Excellence for Nano, Micro andPhotonics Systems) to create a new product. DSC will retain rights to both theproduct and the IP resulting from its creation. Says Mike Pitkethly, CEO of Cenamps, "Durham Scientific Crystals hasdemonstrated a continued ability to innovate boldly and with great success.Cenamps is delighted to support the continued development of a regional companythat has world-wide potential." Motif BioSciences, Inc. Motif recently announced a relationship with the Shafallah Centre for Childrenwith Special Needs, which opened last month in Doha, Qatar. Motif BioSciences,Inc., played an instrumental role in the design and development of the ShafallahCentre's Genetics Medical Centre, assisting in the procurement, identifyingleading instrument vendors, and assisting in the installation of afirst-of-its-kind genetics laboratory dedicated to conducting research ondisorders that afflict the children of Qatar. Motif is delighted to today announce the hire of Zaki Hosny as deputy chairmanand chief executive officer. Mr. Hosny comes to Motif from Merck and Company,Inc., where he most recently held the position of vice president of marketingand operations for Europe, the Middle East and Africa. In that role, he wasresponsible for the development of marketing strategies for the entire productportfolio of the region. Prior to that he was the vice president and regionaldirector for Merck's mid-European region, and during that time he successfullysupervised business units with sales of over $1 billion. Axcess International Inc. AXCESS International, Inc., a leading provider of Radio Frequency Identification(RFID) systems, last week completed an additional capital raise of $1.2 million,bringing the total raised in the recent campaign to $3.5 million. The funds areto be used in part to complete the development of a new RFID product designed tofurther exploit AXCESS' existing markets utilising asset, personnel, and vehicletagging. AXCESS booked record RFID revenue of $453,563 for the first quarter of 2006, anincrease of 88% from the same quarter in 2005 and 9% from the fourth quarter of2005. On 6 June 2006, AXCESS announced a solution for managing and securing criticalcomputer assets which hold privacy data. The ActiveTagTM RFID solution isapplicable to data centres, record departments and enterprise operations wherecomputer assets must be accounted for and protected to be in compliance withFederal and State Laws. Supertron, Inc. Supertron presented at the May 2006 show of the International Society forMagnetic Resonance in Medicine (ISMRM), where they displayed the first-evercommercially available superconducting coils for magnetic resonance imaging(MRI) machines. The products had an outstanding reception and Supertron expectsthem to ship later in 2006. WellGen, Inc. Amphion mourns with great sorrow the sudden and unexpected passing last week ofDr. David Evans, CEO of WellGen. Our thoughts remain with his co-workers andhis family. WellGen today announces the addition to its management team of Steve Sisk asdirector of clinical operations. Steve Sisk has a background including morethan 10 years of pharmaceutical and biotech industry experience (including NovoNordisk, Nektar Therapeutics and Applied Biosystems) involving CRO managementand negotiations, clinical study planning and the execution and direction oflarge cross-functional development teams. Steve received his BS in plantgenetics from Cornell University and his MS from the University of Wisconsin,where he specialised in plant biochemistry and natural products drugs. Richard Mansell-Jones, Chairman of Amphion, said: "We are delighted with the strong progress made by our Partner Companies sincethe March release of our preliminaries. "We look towards the remainder of 2006 with great confidence." Enquiries: Amphion Innovations plcRichard Morgan, Chief Executive +1 (212) 210-6224Aaron Kwittken, Media Relations +1 (646) 747-7144 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert Notes to editors: About Amphion Innovations plc Amphion Innovations plc is quoted on AIM market of the London Stock Exchangeunder the symbol AMP. Amphion's business is the formation, financing,management and development of life sciences and technology companies, working inpartnership with corporations, governments, universities and entrepreneursseeking to commercialise their intellectual property. This information is provided by RNS The company news service from the London Stock Exchange